Brii Biosciences Limited · HKEX:2137
Brii Biosciences — Investor Presentation (November 2021)
22 slides from Brii Biosciences's investor presentation, November 2021
Slide 1: Corporate Presentation
NOVEMBER 2021 Corporate Presentation
Slide 2: Disclaimer
Disclaimer • This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchas
Slide 3: Brii Bio Vision & Mission
Brii Bio Vision & Mission Our vision is to Our mission is to Be the leading public health-inspired and infectious Tackle world’s biggest public health challenges with diseases / CNS diseases-focused biotech Breakthrough Innovation & Insight Value creation through strong Prioritize the access to Leve
Slide 4: Brii's pipeline investment is aligned with China vs. Global market potential
Brii’s pipeline investment is aligned with China vs. Global market potential Without effective cure, many diseases’ prevalence and burden are increasing China is a major market for HBV US and EU are the major markets for HIV Cure and MDR/XDR hospital infection and CNS diseases infections Brii Rights
Slide 5: Broad pipeline addressing large disease burdens in China & globally
Broad pipeline addressing large disease burdens in China & globally Licensing Regulatory Indication Program Preclinical IND Approval Phase 1 Phase 2 Phase 3 Brii Rights Partners/Internally Authority Discovered Infectious Disease Programs BRII-179 (VBI-2601) NMPA Greater China Hepatitis B BRII-835 (V
Slide 6: World-class leadership team with a proven track record of success
World-class leadership team with a proven track record of success Leadership team Jean-Luc GIRARDET Qing ZHU Coy Stout Lisa BECK Lianhong XU SVP, Head of U.S. Market SVP SVP SVP SVP Access and Patient Advocacy Pharmaceutical Science Biopharma BD & Portfolio Management Medicinal Chemistry Former VP o
Slide 7: The importance of HBV functional cure in China
The importance of HBV functional cure in China Hepatitis B Current standard of care FUNCTIONAL CURE Nucleotide/nucleoside reverse transcriptase A sustained functional cure is transformational to patients’ life inhibitors (NRTIs) and interferon • Elimination of social stigma and risk of end-stage Def
Slide 8: Brii Bio HBV cure built on differentiated scientific insight
Brii Bio HBV cure built on differentiated scientific insight Hepatitis B Mechanism of action of BRII-179 and BRII-835 Innate immune responses Adaptive immune responses Other NK cells Stimulation BRII-179 cells IFN-α Virion DC8* cells HBV-specific B-cell Induction of antiviral effectors Effect throug
Slide 9: BRII-835 & BRII-179: Step change approach in the search for an HBV cure
BRII-835 & BRII-179: Hepatitis B Step change approach in the search for an HBV cure BRII-835 (VIR-2218) demonstrates safety and BRII-179 induced both HBV specific B- & T- cell BRII-179/BRII-835 antiviral activity in patients(1) responses in CHB patients(2) combination study HBsAg change from baselin
Slide 10: Brii's combination strategies lead the search for a cure
Brii’s combination strategies lead the search for a cure Hepatitis B Planned or considered combinations China IND approval for Phase 2 combination Phase 2 combination study study is ongoing received in August 2021 BRII-179 Brii Additional BRII-179 combinations PEG-IFN-α BRII-835 HBV CURE Additional
Slide 11: BRII-196 & BRII-198: antibody therapy for treatment of COVID-19
BRII-196 & BRII-198: antibody therapy for treatment of COVID-19 COVID-19 Derived from fully human neutralizing Retained antiviral activity against variants Highlights and MOA antibodies, 1F11 and 1G5, respectively(1) of concern • Current in vitro pseudovirus testing data • Complete neutralization wi
Slide 12: BRII-196 & BRII-198: Phase 3 development for COVID-19
BRII-196 & BRII-198: Phase 3 development for COVID-19 COVID-19 Global Phase 3 Ongoing China Phase 2 ongoing Next Steps and Plans • The Phase 2 clinical trial in China is Randomized double-blind, placebo-controlled Phase 2/3 platform study ongoing led by Dr. Nanshan Zhong, the • Complete Phase 2/3 •
Slide 13: Patients will play a more active role in the growing HIV market
Patients will play a more active role in the growing HIV market HIV infection Advancement of HIV treatment Current SoC: once daily single New treatment options include Aspirational once weekly (QW) 39 1.7 tablet regimen (STR) oral once monthly (QM) & Q2M oral therapies Million Million 690,000 therap
Slide 14: A new treatment option for patients: once weekly single tablet regimen (STR)
A new treatment option for patients: HIV infection once weekly single tablet regimen (STR) New once weekly oral treatment Value Proposition option for HIV patients Goal: Develop a once weekly (QW) oral single tablet The Once Weekly Single Tablet Regimen regimen (STR) for treatment of HIV infection (
Slide 15: Increasing MDR/XDR drives critical unmet clinical needs in China
MDR/XDR Increasing MDR/XDR drives critical unmet clinical needs in China gram-negative infections Unmet Medical Need and Fields for Innovation A serious worldwide threat to public health Resistance rates of the two most prevalent carbapenems in China Drug Resistance Rate to Imipenem and Meropenem (2
Slide 16: Brii antibiotics address complicated & life-threatening infections
MDR/XDR Brii antibiotics address complicated & life-threatening infections gram-negative infections Brii - Qpex hospital antibiotics portfolio Program Modality MOA Pre-clinical Phase 1 Phase 2 Collaborator Milestones Clinical Development Plan • Phase 1 SAD/MAD study ongoing in Australia, which will
Slide 17: Brii - Qpex potential best-in-class beta-lactamase inhibitor (BLI)
MDR/XDR Brii - Qpex potential best-in-class beta-lactamase inhibitor (BLI) gram-negative infections Broadest Coverage across Gram-negative Pathogens and Enzyme Classes CRE CRE Inhibitor Combo Stage ESBLs CRPA Pseudomonas CRAB Acinetobacter Serine-Pro Metallo-Pro BRII-636 (QPX-7728) / Undisclosed IV
Slide 18: Depression is associated with many CNS and other chronic diseases
Depression is associated with many CNS and other chronic diseases PPD MDD Postpartum depression affects both woman The burden of depression is on the rise globally health and neonate development Large and growing PPD patient base Up to one-third of individuals with a serious medical condition have f
Slide 19: ...but it is a very complicated treatment option
Zulresso is the only approved therapeutic for PPD PPD MDD …but it is a very complicated treatment option Mechanism of action of Allopregnanolone in PPD • Allopregnanolone (also known as brexanolone) is a naturally occurring steroid that acts as a positive allosteric modulator (PAM) of GABA's action
Slide 20: BRII-296: a new treatment paradigm & differentiated value proposition
BRII-296: a new treatment paradigm & differentiated value proposition PPD MDD Program Modality MOA Pre-clinical Ph I Ph III Collaborator Milestones BRII-296 Ph1 started April 2021 GABAa PAM Wholly owned PPD Ph3 to start H1 2022 BRII-296 Novel long-acting GABAa PAM Wholly owned Under consideration PP
Slide 21: Upcoming Milestones and Catalysts
Upcoming Milestones and Catalysts Key events Timing BRII-179 Enrollment Enroll 1st patient into Phase 2 study with BRII-179 and pegylated interferon in China 1Q 2022 Data Final CSR report for Phase 2 study in Mainland China 2H 2021 Hepatitis B BRII-835 Data Additional data readout for Phase 2 combo
Slide 22: Contact: ir@briibio.com
Brij Biosciences Breakthrough innovation & insight Contact: ir@briibio.com
Brii Biosciences — Investor Presentation (November 2021) on 6ix